Denali Therapeutics (DNLI) Receivables - Net (2018 - 2025)
Historic Receivables - Net for Denali Therapeutics (DNLI) over the last 8 years, with Q3 2025 value amounting to $1.9 million.
- Denali Therapeutics' Receivables - Net rose 3571.43% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 3571.43%. This contributed to the annual value of $2.2 million for FY2024, which is 3652.05% down from last year.
- According to the latest figures from Q3 2025, Denali Therapeutics' Receivables - Net is $1.9 million, which was up 3571.43% from $1.4 million recorded in Q2 2025.
- Denali Therapeutics' Receivables - Net's 5-year high stood at $15.2 million during Q2 2021, with a 5-year trough of $1.4 million in Q2 2024.
- Over the past 5 years, Denali Therapeutics' median Receivables - Net value was $1.9 million (recorded in 2024), while the average stood at $3.7 million.
- As far as peak fluctuations go, Denali Therapeutics' Receivables - Net soared by 497266.67% in 2021, and later plummeted by 6315.45% in 2023.
- Denali Therapeutics' Receivables - Net (Quarter) stood at $15.2 million in 2021, then crashed by 39.01% to $9.3 million in 2022, then tumbled by 63.15% to $3.4 million in 2023, then plummeted by 56.14% to $1.5 million in 2024, then grew by 26.67% to $1.9 million in 2025.
- Its Receivables - Net stands at $1.9 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.7 million for Q1 2025.